肠道微生物改变与慢性肾脏病的关系密切,尤其是终末期肾脏病腹膜透析患者。本文探讨了肠道微生物群落的组成和功能变化与腹膜透析患者的关系,包括对腹膜透析腹膜炎、炎症反应、技术失败、营养状态等方面的影响。同时,也介绍了调节肠道...肠道微生物改变与慢性肾脏病的关系密切,尤其是终末期肾脏病腹膜透析患者。本文探讨了肠道微生物群落的组成和功能变化与腹膜透析患者的关系,包括对腹膜透析腹膜炎、炎症反应、技术失败、营养状态等方面的影响。同时,也介绍了调节肠道微生物以改善腹膜透析患者预后的潜在策略。Alterations in gut microbiota are closely related to chronic kidney disease, especially in patients with end-stage renal disease undergoing peritoneal dialysis. This article explores the relationship between the composition and functional changes of gut microbial communities and patients undergoing peritoneal dialysis, including their impact on peritoneal dialysis-associated peritonitis, inflammatory responses, technical failure, nutritional status, and other aspects. Additionally, it introduces potential strategies for modulating gut microbiota to improve the prognosis of peritoneal dialysis patients.展开更多
随着慢性肾脏病(CKD)发病率的逐年上升,腹膜透析(PD)作为肾脏替代治疗的重要手段之一,在延长患者生命、改善生活质量方面发挥重要作用。腹膜透析患者的心血管钙化问题也因此受到关注,成为影响其预后的重要因素。本文将从腹膜透析患者心...随着慢性肾脏病(CKD)发病率的逐年上升,腹膜透析(PD)作为肾脏替代治疗的重要手段之一,在延长患者生命、改善生活质量方面发挥重要作用。腹膜透析患者的心血管钙化问题也因此受到关注,成为影响其预后的重要因素。本文将从腹膜透析患者心血管钙化的发生机制、评估手段、危险因素、生物标志物及防治策略等方面,对其近期研究进展进行综述,旨在为临床防治提供理论依据。With the increasing incidence of chronic kidney disease (CKD) year by year, peritoneal dialysis (PD), as one of the important means of kidney replacement therapy, plays an important role in prolonging patients’ lives and improving their quality of life. Therefore, the cardiovascular calcification of peritoneal dialysis patients has been concerned and has become an important factor affecting the prognosis. This article reviews the recent research progress of cardiovascular calcification in peritoneal dialysis patients from the aspects of its pathogenesis, evaluation methods, risk factors, biomarkers and prevention and treatment strategies, aiming at providing theoretical basis for clinical prevention and treatment.展开更多
目的:探究尿毒症肌少症患病率及危险因素。方法:采用Cochrane系统评价的方法,计算机检索Pubmed、Web of sience、Embase、Cochrane、CNKI、CBM、Wanfang、VIP数据库,纳入尿毒症肌少症患病情况的相关研究,采用Stata15.1、Revman5.3进行...目的:探究尿毒症肌少症患病率及危险因素。方法:采用Cochrane系统评价的方法,计算机检索Pubmed、Web of sience、Embase、Cochrane、CNKI、CBM、Wanfang、VIP数据库,纳入尿毒症肌少症患病情况的相关研究,采用Stata15.1、Revman5.3进行统计分析。结果:最终纳入23篇文献,其中病例组1 046例,对照组2 606例。Meta分析结果显示,尿毒症肌少症患病率为25%,亚组分析发现血透患者患病率为29%,腹透患者患病率为15%。尿毒症肌少症影响因素包括营养评分[OR=3.33,95%CI(2.44,4.56),P<0.001]、男性[OR=2.55,95%CI(1.54,4.32),P<0.001]、超敏C反应蛋白[OR=1.38,95%CI(1.19,1.59),P<0.001]、透析龄[OR=1.11,95%CI(1.05,1.16),P<0.001]、细胞外水分[OR=1.09,95%CI(1.06,1.13),P<0.001]、年龄[OR=1.08,95%CI(0.99,1.18),P=0.080],BMI[OR=0.83,95%CI(0.77,0.89),P<0.001]。结论:尿毒症患者肌少症发病率较高,血透患病率高于腹透。其中男性、高龄、透析龄长、高细胞外水分、高超敏C反应蛋白、高营养评分、低BMI是尿毒症肌少症的独立危险因素,应早期筛查,及时干预,以减少肌少症的发生发展。展开更多
文摘肠道微生物改变与慢性肾脏病的关系密切,尤其是终末期肾脏病腹膜透析患者。本文探讨了肠道微生物群落的组成和功能变化与腹膜透析患者的关系,包括对腹膜透析腹膜炎、炎症反应、技术失败、营养状态等方面的影响。同时,也介绍了调节肠道微生物以改善腹膜透析患者预后的潜在策略。Alterations in gut microbiota are closely related to chronic kidney disease, especially in patients with end-stage renal disease undergoing peritoneal dialysis. This article explores the relationship between the composition and functional changes of gut microbial communities and patients undergoing peritoneal dialysis, including their impact on peritoneal dialysis-associated peritonitis, inflammatory responses, technical failure, nutritional status, and other aspects. Additionally, it introduces potential strategies for modulating gut microbiota to improve the prognosis of peritoneal dialysis patients.
文摘随着慢性肾脏病(CKD)发病率的逐年上升,腹膜透析(PD)作为肾脏替代治疗的重要手段之一,在延长患者生命、改善生活质量方面发挥重要作用。腹膜透析患者的心血管钙化问题也因此受到关注,成为影响其预后的重要因素。本文将从腹膜透析患者心血管钙化的发生机制、评估手段、危险因素、生物标志物及防治策略等方面,对其近期研究进展进行综述,旨在为临床防治提供理论依据。With the increasing incidence of chronic kidney disease (CKD) year by year, peritoneal dialysis (PD), as one of the important means of kidney replacement therapy, plays an important role in prolonging patients’ lives and improving their quality of life. Therefore, the cardiovascular calcification of peritoneal dialysis patients has been concerned and has become an important factor affecting the prognosis. This article reviews the recent research progress of cardiovascular calcification in peritoneal dialysis patients from the aspects of its pathogenesis, evaluation methods, risk factors, biomarkers and prevention and treatment strategies, aiming at providing theoretical basis for clinical prevention and treatment.
文摘目的:探究尿毒症肌少症患病率及危险因素。方法:采用Cochrane系统评价的方法,计算机检索Pubmed、Web of sience、Embase、Cochrane、CNKI、CBM、Wanfang、VIP数据库,纳入尿毒症肌少症患病情况的相关研究,采用Stata15.1、Revman5.3进行统计分析。结果:最终纳入23篇文献,其中病例组1 046例,对照组2 606例。Meta分析结果显示,尿毒症肌少症患病率为25%,亚组分析发现血透患者患病率为29%,腹透患者患病率为15%。尿毒症肌少症影响因素包括营养评分[OR=3.33,95%CI(2.44,4.56),P<0.001]、男性[OR=2.55,95%CI(1.54,4.32),P<0.001]、超敏C反应蛋白[OR=1.38,95%CI(1.19,1.59),P<0.001]、透析龄[OR=1.11,95%CI(1.05,1.16),P<0.001]、细胞外水分[OR=1.09,95%CI(1.06,1.13),P<0.001]、年龄[OR=1.08,95%CI(0.99,1.18),P=0.080],BMI[OR=0.83,95%CI(0.77,0.89),P<0.001]。结论:尿毒症患者肌少症发病率较高,血透患病率高于腹透。其中男性、高龄、透析龄长、高细胞外水分、高超敏C反应蛋白、高营养评分、低BMI是尿毒症肌少症的独立危险因素,应早期筛查,及时干预,以减少肌少症的发生发展。
